As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & ...

Prosper Stars & Stripes, a long/short equity fund, recently released its first quarter 2025 investor letter. A copy of the ...

Called Evinova, the new unit has emerged with alliances already in place with contract research organisations Parexel and Fortrea ... and planning of new clinical trials, drawing on artificial ...

Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the ...

"His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Unfortunately, delays and bureaucratic hurdles have steadily eroded the pharmaceutical industry’s enthusiasm for recruiting UK patients for large-scale clinical trials. The 2023 report by Lord O ...

Medpace has a strong financial position with high profit margins and low debt. Click here to read more about MEDP stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Randomized controlled trials are clinical trials in which at least two interventions — the test treatment and a control treatment — are simultaneously evaluated in two or more arms of the ...